Skip to main content

Table 3 Diarrhea-associated events

From: A randomized controlled pilot study to evaluate the effect of an enteral formulation designed to improve gastrointestinal tolerance in the critically ill patient—the SPIRIT trial

  Peptamen® AF (n = 46) Isosource® Energy (n = 44) Treatment effect p value
  n n (%) with event n n (%) with event Risk ratio (95% CI)  
Patients that experienced diarrhea during their ICU stay 45 29 (64%) 44 31 (70%) 0.91 (0.68–1.22) 0.65
Patients receiving a fecal collector during their ICU stay 45 23 (51%) 44 24 (55%) 0.94 (0.63–1.39) 0.83
  n No. of events (pd) n No. of events (pd) Rate ratio (95% CI)  
Days with interruption of EN due to diarrhea 46 0 (253 pd) 44 2 (287 pd) nd 0.28
  n Median (IQR) n Median (IQR) Median difference a (95% CI)  
Total costs of diarrhea per patient/day, CHF 45 3.66 (0.00–8.73) 44 2.60 (0.00–6.39) 0.00
(−0.36 to 2.70)
0.35
Nurse workload per patient/day, min 45 17.0 (0.0–38.5) 44 13.1 (0.0–21.5) 2.5 (−0.7 to 11.8) 0.28
  1. a Hodges–Lehman median differences
  2. CI confidence interval, EN enteral nutrition, ICU intensive care unit, IQR interquartile range, nd not defined, pd person days